Highest Paid Healthcare CEOs, 2024

David Ricks of Eli Lilly leads U.S. healthcare with $15.0M in reported total compensation in the most recent fiscal year, as disclosed in the company's SEC DEF 14A proxy statement. Healthcare-CEO compensation is shaped by long pharmaceutical R&D cycles, FDA approval risk, and patent expirations — which together make multi-year performance share units (PSUs) tied to pipeline milestones a particularly common feature of these packages.

Healthcare CEOs in this ranking average $10.6M in total compensation, with the top 10 averaging $12.3M. Pharmaceutical and biotech CEOs typically earn higher compensation than medical-device or health-insurance CEOs at comparable revenue scales, reflecting (a) the long, expensive, and high-failure-rate R&D cycles that gate revenue in pharma and (b) the multi-year PSU vesting windows that tie large blocks of equity to FDA approvals, peak-sales targets, or relative-TSR-versus-pharma-peer performance.

Three things. (1) Pipeline-linked PSUs — performance metrics often include pipeline-progression milestones (Phase 3 starts, FDA filings, approvals) rather than purely financial targets. (2) Long performance periods — three-to-five-year windows are more common in pharma than the three-year industry standard, reflecting drug-development timelines. (3) Heavy use of TSR-relative-to-peers as a modifier, with peer groups often drawn from a published industry index (e.g., the NYSE Arca Pharmaceutical Index or a custom 12-15-company set of large-cap pharma peers).

Health-insurance CEOs (UnitedHealth, Elevance, Humana, Cigna, CVS Health) consistently rank among the highest-paid in any sector while operating businesses that are politically and reputationally exposed on issues of denial rates, prior authorization, and Medicare Advantage star ratings. The CEO-to-median-worker pay ratio at these companies — often in the 200:1 to 400:1 range — also draws scrutiny under the SEC pay-ratio rule. Say-on-pay vote shares in the sector tend to be lower than the S&P 500 median.

Every figure on this page comes from each healthcare company's most recent SEC DEF 14A proxy statement, available on SEC EDGAR. The Summary Compensation Table inside the filing is the authoritative document; equity awards are reported at FASB ASC 718 grant-date fair value rather than realized pay. Pay-for-Performance Grades are computed using the four-factor framework documented on the methodology page.